JP2003535844A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535844A5 JP2003535844A5 JP2002501818A JP2002501818A JP2003535844A5 JP 2003535844 A5 JP2003535844 A5 JP 2003535844A5 JP 2002501818 A JP2002501818 A JP 2002501818A JP 2002501818 A JP2002501818 A JP 2002501818A JP 2003535844 A5 JP2003535844 A5 JP 2003535844A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- aryl
- het
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxycarbonyl group Chemical group 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 24
- 125000001424 substituent group Chemical group 0.000 description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 11
- 239000000203 mixture Chemical class 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Chemical group 0.000 description 5
- 239000001301 oxygen Chemical group 0.000 description 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 4
- 0 CC(*)(C=C(C=C1)C(N*)=N)C=C1NC(N(*)C(*)C(N*C(*)(*)*)=O)=* Chemical compound CC(*)(C=C(C=C1)C(N*)=N)C=C1NC(N(*)C(*)C(N*C(*)(*)*)=O)=* 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 description 1
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00112116.9 | 2000-06-06 | ||
| EP00112116A EP1162194A1 (en) | 2000-06-06 | 2000-06-06 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| PCT/EP2001/006029 WO2001094301A2 (en) | 2000-06-06 | 2001-05-26 | Factor viia inhibitory (thio)urea derivatives, their preparation and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003535844A JP2003535844A (ja) | 2003-12-02 |
| JP2003535844A5 true JP2003535844A5 (https=) | 2008-05-15 |
| JP4809570B2 JP4809570B2 (ja) | 2011-11-09 |
Family
ID=8168926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002501818A Expired - Fee Related JP4809570B2 (ja) | 2000-06-06 | 2001-05-26 | 第ＶＩＩａ因子阻害剤である（チオ）尿素誘導体、その製造方法およびその使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6743790B2 (https=) |
| EP (2) | EP1162194A1 (https=) |
| JP (1) | JP4809570B2 (https=) |
| KR (1) | KR101011345B1 (https=) |
| CN (1) | CN1208314C (https=) |
| AR (1) | AR030936A1 (https=) |
| AU (2) | AU7749401A (https=) |
| BR (1) | BR0111264A (https=) |
| CA (1) | CA2410862C (https=) |
| CZ (1) | CZ20023963A3 (https=) |
| DE (1) | DE60139320D1 (https=) |
| DK (1) | DK1299354T3 (https=) |
| EE (1) | EE200200617A (https=) |
| ES (1) | ES2330412T3 (https=) |
| HR (1) | HRP20020961A2 (https=) |
| HU (1) | HUP0301631A2 (https=) |
| IL (2) | IL153220A0 (https=) |
| MX (1) | MXPA02009789A (https=) |
| MY (1) | MY129363A (https=) |
| NO (1) | NO328546B1 (https=) |
| NZ (1) | NZ522960A (https=) |
| PL (1) | PL359584A1 (https=) |
| PT (1) | PT1299354E (https=) |
| RU (1) | RU2286337C2 (https=) |
| SK (1) | SK17032002A3 (https=) |
| TW (1) | TWI283662B (https=) |
| WO (1) | WO2001094301A2 (https=) |
| YU (1) | YU89202A (https=) |
| ZA (1) | ZA200209018B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003226755A1 (en) | 2002-04-27 | 2003-11-17 | Merck Patent Gmbh | Carboxylic acid amides |
| JP2005535710A (ja) * | 2002-08-09 | 2005-11-24 | トランス テック ファーマ，インコーポレイテッド | アリールおよびヘテロアリール化合物ならびに凝固を調節する方法 |
| WO2004113278A2 (en) * | 2003-05-20 | 2004-12-29 | Genentech, Inc. | Acylsulfamide inhibitors of factor viia |
| AU2004249671A1 (en) * | 2003-05-20 | 2004-12-29 | Genentech, Inc. | Benzofuran inhibitors of factor VIIa |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7501538B2 (en) * | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| WO2005014533A2 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2006041119A1 (ja) * | 2004-10-13 | 2006-04-20 | Eisai R & D Management Co., Ltd. | ヒドラジド誘導体 |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2006089953A1 (en) * | 2005-02-24 | 2006-08-31 | Novo Nordisk Health Care Ag | Compounds for stabilizing factor vii polypeptide formulations |
| WO2006089954A2 (en) * | 2005-02-24 | 2006-08-31 | Novo Nordisk Health Care Ag | Compounds for stabilizing factor vii polypeptide formulations |
| JP2008531523A (ja) * | 2005-02-24 | 2008-08-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチド製剤を安定化する化合物 |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| CA2647423C (en) | 2006-03-24 | 2015-02-17 | Eisai R&D Management Co., Ltd. | Triazolone derivative |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| US8937181B2 (en) * | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| TW200815353A (en) * | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| WO2009038157A1 (ja) | 2007-09-21 | 2009-03-26 | Eisai R & D Management Co., Ltd. | ２，３－ジヒドロ－イミノイソインドール誘導体 |
| US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| AU2012329098B2 (en) | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| ES2711363T3 (es) * | 2012-04-16 | 2019-05-03 | Allergan Inc | Derivados de (2-ureidoacetamido)alquilo como moduladores del receptor 2 de péptidos formilados |
| US20150273027A1 (en) * | 2012-10-10 | 2015-10-01 | Novo Nordisk Healthcare Ag | Liquid pharmaceutical composition of factor vii polypeptide |
| AU2014225992B2 (en) | 2013-03-06 | 2018-03-22 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| KR102223384B1 (ko) | 2013-03-06 | 2021-03-05 | 알러간, 인코포레이티드 | 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| WO1992013552A1 (en) * | 1991-02-05 | 1992-08-20 | Smithkline Beecham Corporation | Anti-aggregatory peptides containing an aromatic ester or amide |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| JP3387948B2 (ja) * | 1992-12-04 | 2003-03-17 | 富山化学工業株式会社 | 新規なフェニルアラニン誘導体またはその塩 |
| US5314902A (en) | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| DE4309867A1 (de) * | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
| GB9313268D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Chemical compounds |
| GB9313269D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Allophanic acid derivatives |
| WO1995008550A1 (en) * | 1993-09-24 | 1995-03-30 | Abbott Laboratories | Endothelin antagonists |
| WO1995011228A1 (en) * | 1993-10-19 | 1995-04-27 | Sumitomo Pharmaceuticals Co., Ltd. | 2,3-diaminopropionic acid derivative |
| US5674894A (en) * | 1995-05-15 | 1997-10-07 | G.D. Searle & Co. | Amidine derivatives useful as platelet aggregation inhibitors and vasodilators |
| AU712504B2 (en) * | 1996-01-30 | 1999-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| IL135488A0 (en) * | 1997-11-18 | 2001-05-20 | Teijin Ltd | Cyclic amine derivatives |
| EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
-
2000
- 2000-06-06 EP EP00112116A patent/EP1162194A1/en not_active Withdrawn
-
2001
- 2001-05-26 CA CA002410862A patent/CA2410862C/en not_active Expired - Fee Related
- 2001-05-26 YU YU89202A patent/YU89202A/sh unknown
- 2001-05-26 PL PL01359584A patent/PL359584A1/xx not_active Application Discontinuation
- 2001-05-26 RU RU2002135308/04A patent/RU2286337C2/ru not_active IP Right Cessation
- 2001-05-26 EE EEP200200617A patent/EE200200617A/xx unknown
- 2001-05-26 NZ NZ522960A patent/NZ522960A/en unknown
- 2001-05-26 HR HRP20020961 patent/HRP20020961A2/hr not_active Application Discontinuation
- 2001-05-26 ES ES01955291T patent/ES2330412T3/es not_active Expired - Lifetime
- 2001-05-26 AU AU7749401A patent/AU7749401A/xx active Pending
- 2001-05-26 SK SK1703-2002A patent/SK17032002A3/sk not_active Application Discontinuation
- 2001-05-26 CN CNB018088309A patent/CN1208314C/zh not_active Expired - Fee Related
- 2001-05-26 PT PT01955291T patent/PT1299354E/pt unknown
- 2001-05-26 MX MXPA02009789A patent/MXPA02009789A/es active IP Right Grant
- 2001-05-26 IL IL15322001A patent/IL153220A0/xx unknown
- 2001-05-26 KR KR1020027016691A patent/KR101011345B1/ko not_active Expired - Fee Related
- 2001-05-26 CZ CZ20023963A patent/CZ20023963A3/cs unknown
- 2001-05-26 AU AU2001277494A patent/AU2001277494B2/en not_active Ceased
- 2001-05-26 WO PCT/EP2001/006029 patent/WO2001094301A2/en not_active Ceased
- 2001-05-26 HU HU0301631A patent/HUP0301631A2/hu unknown
- 2001-05-26 DK DK01955291T patent/DK1299354T3/da active
- 2001-05-26 DE DE60139320T patent/DE60139320D1/de not_active Expired - Lifetime
- 2001-05-26 JP JP2002501818A patent/JP4809570B2/ja not_active Expired - Fee Related
- 2001-05-26 EP EP01955291A patent/EP1299354B1/en not_active Expired - Lifetime
- 2001-05-26 BR BR0111264-3A patent/BR0111264A/pt not_active IP Right Cessation
- 2001-06-04 TW TW090113412A patent/TWI283662B/zh not_active IP Right Cessation
- 2001-06-04 AR ARP010102657A patent/AR030936A1/es active IP Right Grant
- 2001-06-05 MY MYPI20012631A patent/MY129363A/en unknown
- 2001-06-06 US US09/874,318 patent/US6743790B2/en not_active Expired - Lifetime
-
2002
- 2002-11-06 ZA ZA200209018A patent/ZA200209018B/en unknown
- 2002-12-02 IL IL153220A patent/IL153220A/en not_active IP Right Cessation
- 2002-12-03 NO NO20025810A patent/NO328546B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003535844A5 (https=) | ||
| RU2002135308A (ru) | Производные (тио) мочевины, ингибирующие фактор viiа, их получение и применение | |
| TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
| JP2011515398A5 (https=) | ||
| JP2011529029A5 (https=) | ||
| JP2010517946A5 (https=) | ||
| JP2011502958A5 (https=) | ||
| JP2009520685A5 (https=) | ||
| NZ588830A (en) | Inhibitors of protein kinases | |
| JP2013545798A5 (https=) | ||
| NZ515282A (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
| RU2004116916A (ru) | Производные 5,6-биарил-пиразин-2-амида в качестве антагонистов cb1 | |
| JP2013544893A5 (https=) | ||
| JP2007519649A5 (https=) | ||
| JP2004517087A5 (https=) | ||
| JP2011519374A5 (https=) | ||
| IL165611A (en) | 1h - 1,2,4 - triazole - 3 - carboxamide derivatives and pharmaceutical composotions comprising them | |
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| RU2010130559A (ru) | Гербицидные пиридазиновые производные | |
| WO2005041899A3 (en) | Orally available sphingosine 1-phosphate receptor agonists and antagonists | |
| CA2749040A1 (en) | Triazolo and tetrazolo pyrimidine derivatives as hne inhibitors for treating copd | |
| RU2010148570A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
| JP2014523897A5 (https=) | ||
| JP2008517976A5 (https=) | ||
| WO2007071632A3 (en) | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases |